[The treatment of patients with toxic encephalopathy caused by using surrogate psychoactive manganese-containing compounds].
Toxic encephalopathy caused by using surrogate psychoactive manganese-containing compounds was characterized clinically by a combination of parkinsonian, dystonic and pseudobulbar syndromes, eye-movement disturbances, autonomic insufficiency, affective disorders and moderate intellectual and memory impairment. Pharmacotherapeutic efficacy of mexidol has been studied. The results of the study showed that mexidol therapeutic course has a moderate effect on the expression of movement disorders and intellectual and memory impairment. Mexidol treatment significantly reduced severity of affective disorders and improved quality of life and daily activity of patients.
Ismailova
T F
TF
Fedorova
N V
NV
Savchenko
L M
LM
D000293:Adolescent; D000328:Adult; D000975:Antioxidants / Q000627:therapeutic use*; D003071:Cognition / Q000187:drug effects / Q000502:physiology; D004644:Emotions / Q000187:drug effects / Q000502:physiology; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D017895:Manganese Compounds / Q000009:adverse effects*; D020258:Neurotoxicity Syndromes / Q000188:drug therapy* / Q000209:etiology / Q000523:psychology; D010847:Picolines / Q000627:therapeutic use*; D011619:Psychotropic Drugs / Q000009:adverse effects*; D016896:Treatment Outcome
D000975:Antioxidants; D017895:Manganese Compounds; D010847:Picolines; D011619:Psychotropic Drugs; C070020:emoxypine succinate